Custom fit your mAbs downstream process
You have developed a unique monoclonal antibody therapy and it requires a unique manufacturing process. You need a partner who knows the ins and outs of the downstream process and which holistic solutions will work best for you.
Capitalize on Avantor’s technical expertise and consultative approach to improve productivity, maximize resource use and mitigate risk so you can focus on breakthrough innovations. We offer flexible solutions — tailored to your exact needs — that optimize every step of your mAb downstream process. From aseptic, single-use fluid pathways to more efficient buffer management, and effective viral inactivation to quality resins – we help reduce costs and process time and increase downstream yield.
Customize and streamline your mAbs downstream operations
Comprehensive and customized support to reduce viral burden downstream
Our scientists and application specialists understand the complexities of mAbs viral clearance and provide options for removing critical impurities. This consultative approach is supported by innovative products, such as a sustainable alternative, easy-to-use viral inactivation solution, high performance chromatography resins and buffers, and customized, system-agnostic fluid handling technologies. We tailor our approach to meet your needs, and effectively remove the burden of viral and other impurities downstream.
Expert strategies to improve mAb capture productivity
Rely on our scientific and technical expertise to improve the productivity of the protein capture and further chromatography steps with the right choice of high-capacity resins and buffers that meet critical quality attributes and improve protein recovery. This in-depth application knowledge allows us to handle increased upstream titers with faster processing times, decreased costs and better yields for enhanced purification efficiency of your monoclonal antibody.
Integrated buffer preparation solutions that optimize your mAbs process
If in-house buffer preparation is overwhelming, with buffers not being available on time, in the right quality, leading to production process disturbances - then talk to us about how to achieve more process robustness and control with the right buffer prep strategy.
J.T. Baker® Viral Inactivation Solution
Improve viral inactivation efficiency and minimize introduction of impurities.
PROchievA™ recombinant protein A
Enhance your separation power and increase product purity.
Avantor downstream optimization services
Reduce downstream turnaround times and optimize buffer and chromatography resin selection.Our value section
Our Quality Promise
You can depend on our proactive risk management system to deliver the highest quality of GMP raw materials and fluid handling systems. Globally aligned quality standards, regulatory support and a robust supplier audit program ensure our products are compliant, compendial and traceable, so you can run your mAbs downstream process with confidence.
Our Consultative Approach
Our experts collaborate to design your entire downstream fluid pathway tailored to your needs and enhance your buffer preparation, purification and viral clearance process. With our in-depth application knowledge, we integrate discovery, development and delivery to support an efficient and agile mAbs process. Trust Avantor at every step so you’re not late to market due to disruptions or delays.
Our Global Footprint
Avantor's global network of cGMP and ISO-certified manufacturing sites provides a powerful channel and delivery system for critical raw materials and qualified fluid handling technologies. Transparent supply chain redundancy, as well as vertically integrated products and services, ensures downstream success.
Custom fit your downstream process
We collaborate to design flexible solutions for every step in the process — from buffer management to viral inactivation, chromatography and viral clearance — that can be configured for your unique needs.
The evolution of the monoclonal antibodies (mAbs) market has dramatically changed patient care. Advances in technology as well as knowledge about antibody engineering have brought forth a wide range of targeted therapies to address previously unmet medical needs.
To ensure the safety of biopharmaceuticals derived from mammalian cell culture, it is critical biomanufacturing processes can clear or inactivate potential viral contaminants.
Buffer preparation consumes a substantial portion of a manufacturer’s facility footprint and overall cost, labor requirements and equipment. A review of four case studies explores how Avantor customers resolved their buffer management challenges with custom solutions to reduce manufacturing floor space and save time and expenses.
